Cutaneous melanoma: prognostic factors
- PMID: 16258493
- DOI: 10.1177/107327480501200403
Cutaneous melanoma: prognostic factors
Abstract
Background: Recent data have changed our views of prognostic factors in cutaneous melanoma. While some newer methods have yielded better prognostic information, some insights have evolved as a result of large-scale population-based analyses.
Methods: We review current data on several different prognostic factors and divide these factors according to their application in localized primary melanoma or metastatic melanoma. For each prognostic factor, the level of evidence supporting its use and its applicability to clinical practice are considered.
Results: For localized primary melanoma, the dominant predictors of survival include lesion thickness, ulceration, and lymph node involvement. Factors such as age, sex, anatomic location, and satellite/in-transit lesions are important in localized melanoma. Factors currently being investigated are tumor vascularity, vascular invasion, mitotic rate, tumor regression, and tumor-infiltrating lymphocytes. For metastatic melanoma, the most important prognostic factors are site of metastases and the presence of elevated serum lactic dehydrogenase. The value of these prognostic factors to clinicians caring for melanoma patients is discussed.
Conclusions: A better understanding of prognostic factors in cutaneous melanoma has evolved over the last decade, allowing oncologists to provide appropriate treatment for their patients. Many of the prognostic factors are interrelated. In the near future, it is expected that several molecular genetic factors will provide more insight into the prognosis of patients with melanoma.
Similar articles
-
Presence of histological regression as a prognostic factor in cutaneous melanoma patients.Melanoma Res. 2016 Oct;26(5):492-6. doi: 10.1097/CMR.0000000000000277. Melanoma Res. 2016. PMID: 27380112
-
Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma.Melanoma Res. 2007 Dec;17(6):393-9. doi: 10.1097/CMR.0b013e3282f05039. Melanoma Res. 2007. PMID: 17992123
-
Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma.Cancer. 2006 Nov 15;107(10):2436-45. doi: 10.1002/cncr.22295. Cancer. 2006. PMID: 17058288
-
Pathology of melanocytic lesions: new, controversial, and clinically important issues.J Surg Oncol. 2004 Jul 1;86(4):200-11. doi: 10.1002/jso.20083. J Surg Oncol. 2004. PMID: 15221927 Review.
-
Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma.Cancer. 1996 Apr 1;77(7):1303-10. doi: 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5. Cancer. 1996. PMID: 8608507
Cited by
-
Could the mitotic count improve personalized prognosis in melanoma patients?PLoS One. 2024 Apr 16;19(4):e0302309. doi: 10.1371/journal.pone.0302309. eCollection 2024. PLoS One. 2024. PMID: 38626072 Free PMC article.
-
Cancer-associated Fibroblast-specific Expression of the Matricellular Protein CCN1 Coordinates Neovascularization and Stroma Deposition in Melanoma Metastasis.Cancer Res Commun. 2024 Feb 27;4(2):556-570. doi: 10.1158/2767-9764.CRC-23-0571. Cancer Res Commun. 2024. PMID: 38363129 Free PMC article.
-
The reliability and validity of lung cancer and melanoma clinical quality survival measures.Health Serv Res. 2023 Oct;58(5):1131-1140. doi: 10.1111/1475-6773.14164. Epub 2023 May 12. Health Serv Res. 2023. PMID: 37669902
-
Integrating additional factors into the TNM staging for cutaneous melanoma by machine learning.PLoS One. 2021 Sep 30;16(9):e0257949. doi: 10.1371/journal.pone.0257949. eCollection 2021. PLoS One. 2021. PMID: 34591891 Free PMC article.
-
m5C-Related Signatures for Predicting Prognosis in Cutaneous Melanoma with Machine Learning.J Oncol. 2021 Aug 4;2021:6173206. doi: 10.1155/2021/6173206. eCollection 2021. J Oncol. 2021. PMID: 34394351 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
